A pilot study of the effect of the 5-HT-uptake inhibitor, zimelidine, on phobic anxiety.
A new antidepressant, zimelidine, which is a selective inhibitor of 5-HT-uptake, was tested in an open study of 13 patients, in each of whom the principal clinical diagnosis was phobic neurosis. The dose varied from 200 to 300 mg daily. After 6 weeks of treatment, 6 patients dropped out of the study as they were not appreciably improved, but 7 patients definitely improved and completed a treatment course of at least 12 weeks. In these cases it was possible to observe subjective relief of symptoms, improved social function, increased working capacity and a reduced need for anxiolytics. The effect appeared similar to the previously described effects of clomipramine treatment. The incidence of side effects was low and those that occurred were mild. Tolerance was assessed as very good by the great majority of patients. The study suggests that zimelidine has a favourable effect on mild, moderate, and even in some severe phobic conditions. Some comparisons with MAO-inhibitors were made. The results are sufficiently encouraging to suggest a controlled study.
D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000188:drug therapy*; D001835:Body Weight; D001977:Brompheniramine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D008875:Middle Aged; D010076:Oxazepam / Q000627:therapeutic use; D010624:Phenelzine / Q000009:adverse effects / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015031:Zimeldine
D011725:Pyridines; D012702:Serotonin Antagonists; D015031:Zimeldine; D010076:Oxazepam; D001977:Brompheniramine; D010624:Phenelzine